Digital health: how can technology be used to engage hard-to...

Helping someone live with a condition as complex as MS can be fraught with challenges.

Disruption and maturity: the future directions for biologics

Is the UK’s NHS saving enough from the new wave of biosimilars?

The future of the clinical trial: collaboration and patient ...

Approval and access: overcoming the final hurdle of drug dev...

2017 is likely to be a year of significant change for pharma brands in Europe. With affordability on the agenda for almost every country in the region, a move toward greater col